Inhibikase Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Inhibikase Therapeutics

11/11/2022 22:00

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
14. 
    * The Atlanta Georgia-based  company is expected to report 
a
39.1% decrease in revenue to $200 thousand from $328.46 thousand
a year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 18 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6​, above​ its last closing price of $0.48.
​​​

This summary was machine generated November 11 at 22:00 GMT. 
All figures in US dollars  unless otherwise stated